Tags

Type your tag names separated by a space and hit enter

Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Chem Commun (Camb). 2020 Aug 07; 56(61):8683-8686.CC

Abstract

Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.

Authors+Show Affiliations

Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. liuzq@gzucm.edu.cn liao@gzucm.edu.cn.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32613971

Citation

Qi, Xiaoxiao, et al. "Construction and Immunogenic Studies of a mFc Fusion Receptor Binding Domain (RBD) of Spike Protein as a Subunit Vaccine Against SARS-CoV-2 Infection." Chemical Communications (Cambridge, England), vol. 56, no. 61, 2020, pp. 8683-8686.
Qi X, Ke B, Feng Q, et al. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chem Commun (Camb). 2020;56(61):8683-8686.
Qi, X., Ke, B., Feng, Q., Yang, D., Lian, Q., Li, Z., Lu, L., Ke, C., Liu, Z., & Liao, G. (2020). Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chemical Communications (Cambridge, England), 56(61), 8683-8686. https://doi.org/10.1039/d0cc03263h
Qi X, et al. Construction and Immunogenic Studies of a mFc Fusion Receptor Binding Domain (RBD) of Spike Protein as a Subunit Vaccine Against SARS-CoV-2 Infection. Chem Commun (Camb). 2020 Aug 7;56(61):8683-8686. PubMed PMID: 32613971.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. AU - Qi,Xiaoxiao, AU - Ke,Bixia, AU - Feng,Qian, AU - Yang,Deying, AU - Lian,Qinghai, AU - Li,Zibo, AU - Lu,Linlin, AU - Ke,Changwen, AU - Liu,Zhongqiu, AU - Liao,Guochao, Y1 - 2020/07/02/ PY - 2020/7/3/pubmed PY - 2020/8/11/medline PY - 2020/7/3/entrez SP - 8683 EP - 8686 JF - Chemical communications (Cambridge, England) JO - Chem Commun (Camb) VL - 56 IS - 61 N2 - Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine. SN - 1364-548X UR - https://www.unboundmedicine.com/medline/citation/32613971/Construction_and_immunogenic_studies_of_a_mFc_fusion_receptor_binding_domain__RBD__of_spike_protein_as_a_subunit_vaccine_against_SARS_CoV_2_infection_ L2 - https://doi.org/10.1039/d0cc03263h DB - PRIME DP - Unbound Medicine ER -